PA
WST icon

Paragon Advisors’s West Pharmaceutical WST Stock Holding History

Paragon Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,768
Closed -$1.52M – 93
2025
Q1 		$1.52M Buy
6,768
+156
+2% +$43K 0.57% 53
2024
Q4 		$2.17M Sell
6,612
-192
-3% -$60.4K 0.74% 40
2024
Q3 		$2.04M Buy
6,804
+136
+2% +$41.6K 0.66% 45
2024
Q2 		$2.2M Buy
6,668
+2,152
+48% +$761K 0.8% 38
2024
Q1 		$1.79M Buy
4,516
+1,428
+46% +$528K 0.72% 46
2023
Q4 		$1.09M Buy
+3,088
New +$1.09M 0.46% 69
2022
Q2 		– Sell
-2,196
Closed -$902K – 86
2022
Q1 		$902K Buy
2,196
+458
+26% +$179K 0.38% 54
2021
Q4 		$815K Buy
+1,738
New +$748K 0.4% 49

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Paragon Advisors's WST Position: Q2 2025 in Review

Paragon Advisors sold out of West Pharmaceutical (WST) in Q2 2025, closing a stake of 6,768 shares — an estimated $1.52M sold.

Paragon Advisors first reported a position in WST in Q4 2021 and held it in 8 quarters. The position peaked at $2.2M in Q2 2024. 730 funds tracked by Wall St. Rank hold WST as of Q2 2025.

  • Paragon Advisors reported no remaining West Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • Paragon Advisors sold 6,768 West Pharmaceutical shares in Q2 2025, an estimated $1.52M.
  • Paragon Advisors first reported a position in West Pharmaceutical in Q4 2021 and held it in 8 quarters.
  • Paragon Advisors's West Pharmaceutical position peaked at $2.2M in Q2 2024.
  • 730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2025.

Based on Paragon Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.